title: Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas.
abstract: p53 Genetic alterations are associated with advanced stage and aggressive tumors in a variety of human malignancies. The aim of this study was to examine p53 for genetic alterations and to evaluate the association of these alterations with clinical outcome and response to adjuvant radiotherapy in endometrioid endometrial carcinomas. p53 mutations in exons 2-11 were assessed in 59 endometrioid carcinomas by polymerase chain reaction-single-strand conformational polymorphism and sequence analysis. Twelve mutations (20.3%) and nine polymorphisms were identified. Seven of the nine polymorphisms were codon 72 single nucleotide polymorphisms (SNP) with an Arg/Pro allelotype. Women harboring either a mutation or an Arg/Pro allelotype at codon 72 had a lower overall survival rate than women whose tumors lacked alterations in the p53 gene (P= 0.0029). Women were stratified based on p53 genetic alterations (p53 mutation or p53 codon 72 SNP) and whether or not they received adjuvant radiation therapy. Women with p53 genetic alterations who did not receive adjuvant radiotherapy had the lowest survival rate (P= 0.0005). Treated women with p53 genetic alterations and untreated women with no p53 alteration had similar rates of survival. Among women with p53 alterations, adjuvant radiotherapy substantially increased survival (P= 0.035). In multivariate analyses, the group of women with p53 genetic alterations who did not receive adjuvant radiation therapy had a 5.9-fold increased risk of death (95% confidence interval: 1.5-22.7) compared to women whose tumors lacked p53 alterations and did not receive adjuvant radiation therapy.
authors.affiliation: Department of Pathology, University of Southern California School of Medicine, Los Angeles, California 90033, USA.
authors.forename: B
authors.initials: B
authors.lastname: Saffari
authors.forename: L
authors.initials: L
authors.lastname: Bernstein
authors.forename: D C
authors.initials: DC
authors.lastname: Hong
authors.forename: J
authors.initials: J
authors.lastname: Sullivan-Halley
authors.forename: I B
authors.initials: IB
authors.lastname: Runnebaum
authors.forename: H-J
authors.initials: HJ
authors.lastname: Grill
authors.forename: L A
authors.initials: LA
authors.lastname: Jones
authors.forename: A
authors.initials: A
authors.lastname: El-Naggar
authors.forename: M F
authors.initials: MF
authors.lastname: Press
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001483:Base Sequence; D014408:Biomarkers, Tumor; D018269:Carcinoma, Endometrioid / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy*; D003062:Codon / Q000235:genetics; D016889:Endometrial Neoplasms / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy*; D005091:Exons / Q000235:genetics; D005260:Female; D005854:Germ Cells / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; D003062:Codon; D016159:Tumor Suppressor Protein p53